Skip to main content
SpringerLink
Log in

Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease

  • Hepatitis C (K Marks, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

The landscape of therapeutic options for HCV infection has dramatically changed with the approval of all-oral direct-acting antiviral (DAA) regimens. DAAs target important steps in the HCV viral life cycle, resulting in higher response rates and fewer adverse events than were afforded with interferon and ribavirin, the prior standard of care. The achievement of sustained virologic response (SVR) rates in excess of 90% with use of DAA regimens has not only been translated into HCV eradication for the hundreds of thousands treated but is also anticipated to decrease the incidence of major complications associated with chronic HCV infection. Additionally, the favorable side effect profile of DAAs has made HCV therapy feasible in difficult-to-treat populations, including those with previous exposure to interferon and ribavirin, cirrhosis, decompensated liver disease, HIV and HCV co-infection, and severe renal dysfunction/end-stage renal disease. Given this tremendous progress, all patients infected with HCV infection should be treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Choo QL, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359–62.

    Article  CAS  PubMed  Google Scholar 

  2. van der Meer AJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.

    Article  PubMed  Google Scholar 

  3. Mohd Hanafiah K, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.

    Article  PubMed  Google Scholar 

  4. Smith BD, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.

    PubMed  Google Scholar 

  5. Messina JP, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.

    Article  PubMed  Google Scholar 

  6. Harvoni package insert. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.

  7. Viekira XR package insert. http://www.rxabbvie.com/pdf/viekiraxr_pi.pdf.

  8. Zepatier package insert. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.

  9. Epclusa package insert. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf.

  10. Solvaldi package insert. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.

  11. Daklinza package insert. http://packageinserts.bms.com/pi/pi_daklinza.pdf.

  12. Olysio package insert. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf.

  13. •• AASLD/IDSA/IAS-USA HCV guidance: recommendations for testing, managing and treating hepatitis C. http://www.hcvguidelines.org/. 2016.Guidance document outlining suggested hepatitis C treatment regimens based on most up to date research.

  14. Liu R, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015;59(11):6922–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Howe AY, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59(12):1657–65.

    Article  CAS  PubMed  Google Scholar 

  17. • Zeuzem S, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.Phase 3 trial in treatment naive patients supporting the efficacy of the elbasvir/grazoprevir fixed dose combination for treatment of chronic hepatitis C infection.

  18. Kwo P, Gani E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir +/− RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment- experience [Abstract P0886]. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015: Vienna, Austria.

  19. Zeuzem S, Rockstroh JK, Kwo PY et al. Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)-infected patients: integrated analysis of phase 2–3 trials [Abstract 700]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2015: San Francisco, CA.

  20. Buti M, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–6.

    Article  PubMed  Google Scholar 

  21. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A) [Abstract O008]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna, Austria.

  22. •• Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.Manuscript demonstrating efficacy of ledipasvir/sofosbuvir for treatment of chronic hepatitis C infection in treatment naive patients.

  23. •• Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.Study demonstrating non-inferiority of 8 weeks of ledipasvir/sofosbuvir compared to 12 weeks in specific subgroups of patients with hepatitis C infection.

  24. Terrault, N.A., et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–40.

  25. de Ledinghen V FH, Dorival C et al., Safety and efficacy of sofosbuvir-containing regimens in the French obervational cohort ANRS C022 HEPATHER. [Abstract P0795]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna, Austria.

  26. Backus LI, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405–14.

    Article  CAS  PubMed  Google Scholar 

  27. Wilder JM, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016;63(2):437–44.

    Article  CAS  PubMed  Google Scholar 

  28. O’Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis. 2014;1(3):ofu110.

    Article  PubMed  PubMed Central  Google Scholar 

  29. •• Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.Phase 3 trial examining the efficacy of ledipasvir/sofosbuvir for treatment of chronic hepatitis C infection in treatment experienced patients.

  30. Tapper EB, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat, 2017;24(1):22–7.

  31. Bourliere M, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.

    Article  CAS  PubMed  Google Scholar 

  32. Gane EJ, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–43. e1

    Article  CAS  PubMed  Google Scholar 

  33. Lawitz E, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.

    Article  CAS  PubMed  Google Scholar 

  34. Charlton M, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59.

    Article  CAS  PubMed  Google Scholar 

  35. Manns M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–97.

    Article  CAS  PubMed  Google Scholar 

  36. • Ferenci P, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92.Phase 3 clinical trial examining the efficacy and safety of ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for the treatment of chronic hepatitis C infection in treatment naive patients.

  37. • Zeuzem S, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–14.Phase 3 trial demonstrating efficacy and safety of 12 weeks ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for the treatment of chronic hepatitis C infection in treatment experienced patients.

  38. Andreone P, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65. e1

    Article  CAS  PubMed  Google Scholar 

  39. Poordad F, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.

    Article  PubMed  Google Scholar 

  40. Feld JJ, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64(2):301–7.

    Article  CAS  PubMed  Google Scholar 

  41. Everson GT, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):818–26.

    Article  PubMed  Google Scholar 

  42. Pianko S, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):809–17.

    Article  PubMed  Google Scholar 

  43. • Feld JJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.Phase 3 trial demonstrating efficacy of sofosbuvir/velpatasvir for 12 weeks in treatment naive and experienced hepatitis C patients.

  44. Curry MP, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28.

    Article  CAS  PubMed  Google Scholar 

  45. Gao M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.

    Article  CAS  PubMed  Google Scholar 

  46. Sofia MJ, et al. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202–18.

    Article  CAS  PubMed  Google Scholar 

  47. Sulkowski MS, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.

    Article  CAS  PubMed  Google Scholar 

  48. Wyles DL, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.

    Article  CAS  PubMed  Google Scholar 

  49. Poordad F, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Welzel TM, Zeuzem S, Petersen J, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program [Abstract 37]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2015: San Francisco, CA.

  51. Lawitz E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.

    Article  CAS  PubMed  Google Scholar 

  52. Kwo P, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. •• Sarrazin C, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501–12. e1Critical manuscript evaluating the prevalence and treatment outcomes with NS5A, NS5B and NS3 RAVs.

  54. Bourlière M, Gordon SC, Ramji A et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1–6 infection: the phase 3 POLARIS-1 study [Abstract 194]. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2016: Boston, MA.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Drive, 722 Blockley Hall, Philadelphia, PA, 19104, USA

    Kimberly A. Forde MD MHS

  2. Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue CHS 37-121, Los Angeles, CA, 90095, USA

    Debika Bhattacharya MD MSc

Authors
  1. Kimberly A. Forde MD MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Debika Bhattacharya MD MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberly A. Forde MD MHS.

Ethics declarations

Conflict of Interest

Dr. Kimberly Forde declares that she has no conflicts of interest. Dr. Debika Bhattacharya has received research support, paid to her institution, from Abbvie, Merck, and Bristol-Myers Squibb.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forde, K.A., Bhattacharya, D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 9, 262–276 (2017). https://doi.org/10.1007/s40506-017-0124-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0124-x

Keywords

Search

Navigation